Baseline characteristics of 142 consecutive patients receiving 131I-rituximab radioimmunotherapy
| Characteristic . | n . | % . |
|---|---|---|
| Age, y* | ||
| ≥ 60 | 82 | |
| < 60 | 60 | |
| Sex | ||
| Male | 78 | 54.93 |
| Female | 64 | 45.07 |
| Serum LDH | ||
| Normal | 82 | 57.75 |
| High | 48 | 33.80 |
| Unknown | 12 | 8.45 |
| Histology | ||
| Follicular grade | ||
| 1 | 39 | 27.46 |
| 2 | 39 | 27.46 |
| 3 | 16 | 11.27 |
| Mantle | 8 | 5.63 |
| MALT | 6 | 4.23 |
| SLL | 21 | 14.79 |
| Follicular unspecified/low grade | 13 | 9.15 |
| FLIPI | ||
| 0-1 | 37 | 26.06 |
| 2 | 39 | 27.46 |
| ≥ 3 | 29 | 20.42 |
| NA | 36 | 25.35 |
| Unknown | 1 | 0.70 |
| Bone marrow involvement | ||
| Yes | 46 | 32.39 |
| No | 94 | 66.20 |
| Unknown | 2 | 1.41 |
| Prior chemotherapy | ||
| 1 | 87 | 61.27 |
| 2 | 31 | 21.83 |
| ≥ 3 | 24 | 16.90 |
| Last chemo to RIT, mo | ||
| ≤ 6 | 41 | 31.3 |
| > 6 | 90 | 68.7 |
| Prior rituximab | ||
| Yes | 80 | 56.34 |
| No | 60 | 42.25 |
| Unknown | 2 | 1.41 |
| Prior DXRT | ||
| Yes | 42 | 29.58 |
| No | 99 | 69.71 |
| Unknown | 1 | 0.7 |
| Stage at study entry | ||
| I/II | 40 | 28.17 |
| III/IV | 102 | 71.83 |
| Bulky disease (≥ 5 cm) | ||
| Yes | 28 | 19.72 |
| No | 105 | 73.94 |
| Unknown | 9 | 6.34 |
| B2 microglobulin | ||
| Normal | 83 | 58.44 |
| Elevated | 21 | 14.78 |
| Unknown | 38 | 26.76 |
| Characteristic . | n . | % . |
|---|---|---|
| Age, y* | ||
| ≥ 60 | 82 | |
| < 60 | 60 | |
| Sex | ||
| Male | 78 | 54.93 |
| Female | 64 | 45.07 |
| Serum LDH | ||
| Normal | 82 | 57.75 |
| High | 48 | 33.80 |
| Unknown | 12 | 8.45 |
| Histology | ||
| Follicular grade | ||
| 1 | 39 | 27.46 |
| 2 | 39 | 27.46 |
| 3 | 16 | 11.27 |
| Mantle | 8 | 5.63 |
| MALT | 6 | 4.23 |
| SLL | 21 | 14.79 |
| Follicular unspecified/low grade | 13 | 9.15 |
| FLIPI | ||
| 0-1 | 37 | 26.06 |
| 2 | 39 | 27.46 |
| ≥ 3 | 29 | 20.42 |
| NA | 36 | 25.35 |
| Unknown | 1 | 0.70 |
| Bone marrow involvement | ||
| Yes | 46 | 32.39 |
| No | 94 | 66.20 |
| Unknown | 2 | 1.41 |
| Prior chemotherapy | ||
| 1 | 87 | 61.27 |
| 2 | 31 | 21.83 |
| ≥ 3 | 24 | 16.90 |
| Last chemo to RIT, mo | ||
| ≤ 6 | 41 | 31.3 |
| > 6 | 90 | 68.7 |
| Prior rituximab | ||
| Yes | 80 | 56.34 |
| No | 60 | 42.25 |
| Unknown | 2 | 1.41 |
| Prior DXRT | ||
| Yes | 42 | 29.58 |
| No | 99 | 69.71 |
| Unknown | 1 | 0.7 |
| Stage at study entry | ||
| I/II | 40 | 28.17 |
| III/IV | 102 | 71.83 |
| Bulky disease (≥ 5 cm) | ||
| Yes | 28 | 19.72 |
| No | 105 | 73.94 |
| Unknown | 9 | 6.34 |
| B2 microglobulin | ||
| Normal | 83 | 58.44 |
| Elevated | 21 | 14.78 |
| Unknown | 38 | 26.76 |
LDH indicates lactate dehydrogenase; MALT, mucosa-associated lymphoid tissue; DXRT, external beam radiotherapy; and FLIPI, Follicular Lymphoma International Prognostic Index.
Median age, 61 years (range, 30-85 years).